PMID- 19072134
OWN - NLM
STAT- MEDLINE
DCOM- 20090306
LR  - 20211028
IS  - 0022-1899 (Print)
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 199
IP  - 2
DP  - 2009 Jan 15
TI  - Circulating CD23+ B cell subset correlates with the development of resistance to 
      Schistosoma mansoni reinfection in occupationally exposed adults who have 
      undergone multiple treatments.
PG  - 272-9
LID - 10.1086/595792 [doi]
AB  - BACKGROUND: Elevated immunoglobulin E (IgE) levels are often associated with 
      resistance to reinfection in human schistosomiasis. However, Although B cells are 
      the source of schistosome-specific IgE, little is known about B cell subsets or 
      their functions in this infection. We evaluated B cells and their expression of 
      the low-affinity IgE receptor (CD23) in a unique cohort of men occupationally 
      exposed to Schistosoma mansoni and longitudinally followed up through multiple 
      treatments with praziquantel, cures, and reinfections. METHODS: Resistance levels 
      were calculated on the basis of documented water exposure and reinfection data 
      over many years. The CD23(+) B cell subset was evaluated in whole blood by flow 
      cytometry. Serum antibody isotype and soluble CD23 (sCD23) concentrations were 
      measured by enzyme-linked immunosorbent assay. RESULTS: Expression of membrane 
      CD23 (mCD23) on B cells correlated with the development of resistance against S. 
      mansoni. Higher levels of plasma sCD23, the cleaved form of mCD23, also 
      correlated with resistance and other markers of resistance to reinfection, such 
      as eosinophilia. CONCLUSIONS: CD23 may be involved in the development of 
      resistance to schistosome infection through its role in IgE regulation. 
      Understanding these complex host-parasite interactions may lead to insights into 
      the development, mechanisms, and regulation of resistance to reinfection with S. 
      mansoni.
FAU - Mwinzi, Pauline N M
AU  - Mwinzi PN
AD  - Center for Global Health Research, Kenya Medical Research Institute, Kisumu, 
      Kenya.
FAU - Ganley-Leal, Lisa
AU  - Ganley-Leal L
FAU - Black, Carla L
AU  - Black CL
FAU - Secor, W Evan
AU  - Secor WE
FAU - Karanja, Diana M S
AU  - Karanja DM
FAU - Colley, Daniel G
AU  - Colley DG
LA  - eng
GR  - R01 AI053695/AI/NIAID NIH HHS/United States
GR  - R21 AI074843-01A2/AI/NIAID NIH HHS/United States
GR  - T32 AI060546/AI/NIAID NIH HHS/United States
GR  - D43 TW007123/TW/FIC NIH HHS/United States
GR  - R21 AI074843/AI/NIAID NIH HHS/United States
GR  - AI 053692/AI/NIAID NIH HHS/United States
GR  - 083607/WT_/Wellcome Trust/United Kingdom
GR  - D43 T007123W/PHS HHS/United States
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Anthelmintics)
RN  - 0 (Receptors, IgE)
RN  - 6490C9U457 (Praziquantel)
SB  - IM
MH  - Animals
MH  - Anthelmintics/administration & dosage/therapeutic use
MH  - B-Lymphocyte Subsets/*immunology/metabolism
MH  - Eosinophilia
MH  - Humans
MH  - Male
MH  - *Occupational Exposure
MH  - Praziquantel/administration & dosage/therapeutic use
MH  - Receptors, IgE/*metabolism
MH  - Recurrence
MH  - Schistosoma mansoni/*drug effects/pathogenicity
MH  - Schistosomiasis mansoni/*drug therapy/*immunology/parasitology
PMC - PMC2636678
MID - NIHMS89681
EDAT- 2008/12/17 09:00
MHDA- 2009/03/07 09:00
PMCR- 2010/01/15
CRDT- 2008/12/17 09:00
PHST- 2008/12/17 09:00 [entrez]
PHST- 2008/12/17 09:00 [pubmed]
PHST- 2009/03/07 09:00 [medline]
PHST- 2010/01/15 00:00 [pmc-release]
AID - 10.1086/595792 [doi]
PST - ppublish
SO  - J Infect Dis. 2009 Jan 15;199(2):272-9. doi: 10.1086/595792.